






Supplementary Figure 1: Kaplan-Meier estimates of overall survival from the end of MRgRT, stratification was done according to the Indication for MRgRT



Supplementary Figure 2:

A-G: Kaplan-Meier estimates of overall survival from the end of MRgRT, stratified by synchronous versus metachronous onset of metastatic disease (A), oligometastatic versus polymetastatic disease (B), number of metastases (≤ 2 vs. ≥ 3) (C), prescribed dose (40 Gy vs. 33 Gy) (D), addition of metastasis-directed therapy to MRgRT of the primary tumor versus MRgRT of the primary tumor alone (E), number of chemotherapy lines prior to MRgRT (1 vs ≥ 2) (F), and radiographic response of the primary pancreatic tumor to induction chemotherapy (stable disease vs. progressive disease) (G)



Supplementary Figure 3:

A: Kaplan-Meier estimates of local control from the end of MRgRT, stratified by prescribed dose (40 Gy vs. 33 Gy).

B: Kaplan-Meier estimates of time to distant progression from the end of MRgRT, stratified by treatment approach (MRgRT of the primary tumor with vs. without additional metastasis-directed therapy).